<DOC>
	<DOCNO>NCT00031577</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Paclitaxel may make tumor cell sensitive radiation therapy . PURPOSE : Phase I trial study effectiveness combine paclitaxel radiation therapy treat child newly diagnose brain stem glioma .</brief_summary>
	<brief_title>Paclitaxel Plus Radiation Therapy Treating Children With Newly Diagnosed Brain Stem Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose paclitaxel combine involved-field radiotherapy child newly diagnose , diffuse , intrinsic brain stem glioma . - Determine toxicity regimen patient . - Assess antitumor activity regimen patient . OUTLINE : This multicenter , dose-escalation study paclitaxel . Patients receive induction therapy comprise paclitaxel intravenously ( IV ) 1 hour weekly involved-field radiotherapy ( paclitaxel infusion ) daily , 5 day week , 6 week . Beginning 6 week completion induction therapy , patient may receive maintenance therapy comprise paclitaxel IV 1 hour every 3 week total 8 course . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos paclitaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A minimum 12 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose , diffuse , intrinsic brain stem glioma clinical examination magnetic resonance imaging ( MRI ) Histologic verification require Intrinsic ( 50 % intraaxial ) involvement pons , pons medulla , pons midbrain , entire brain stem allow Contiguous involvement thalamus upper cervical cord allow PATIENT CHARACTERISTICS : Age : 3 21 diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,000/mm3 Platelet count great 100,000/mm3 Hemoglobin great 10.0 g/dL Hepatic : Bilirubin le 1.5 time normal serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamicpyruvic transaminase ( SGPT ) less 2.5 time normal Renal : Creatinine le 1.5 time normal Other : Not pregnant nursing Negative pregnancy test Fertile patient must use highly effective method contraception female patient barrier contraception male patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent anticancer chemotherapy Endocrine therapy : Concurrent corticosteroid therapy increase intracranial pressure allow Radiotherapy : Not specify Surgery : Not specify Other : No concurrent cytochrome P450inducing anticonvulsant ( e.g. , phenytoin carbamazepine ) paclitaxel therapy Other concurrent anticonvulsant ( e.g. , valproic acid ) preexisting seizure disorder allow</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>untreated childhood brain stem glioma</keyword>
</DOC>